Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NOVANTA INC insiders sold a net $4.2M of stock across 208 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Nobody has filed for crossing 5%. That is a fact, not missing data.
NOVT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Secor Thomas N
Filed 2026-09-11
$97.9K
Matthijs Glastra
Filed 2026-07-02
$1.1M
NOVT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
CONESTOGA SMALL CAP FUND
$93.5M position · as of 2026-06-30
4.6%
FAM SMALL CAP FUND
$14.1M position · as of 2026-06-30
4.5%
CONESTOGA SMID CAP FUND
$20.2M position · as of 2026-06-30
4.2%
Wasatch U.S. Select Fund
$616.8K position · as of 2026-06-30
3.6%
DF DENT SMALL CAP GROWTH FUND
$6.0M position · as of 2026-06-30
3.5%
Wasatch Long/Short Alpha Fund
$1.3M position · as of 2026-06-30
3.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.0M
$2.4M
$2.6M
+1%
+34%
2024
$8.8M
-$260.0K
$2.6M
+29%
+19%
2023
$8.3M
$14.4M
$2.1M
+42%
+7%
2022
$7.3M
$2.8M
$2.1M
+15%
-9%
2021
$12.4M
$24.5M
$4.2M
+49%
+15%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.2M sold by insiders over 180 days, 243 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $97.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.0B
four quarters, 2025-06-28 to 2026-07-03
Revenue, TTM NOVT
FY Dec 2025
$980.6M
FY Dec 2024
$949.2M
FY Dec 2023
$881.7M
FY Dec 2022
$860.9M
FY Dec 2021
$706.8M
Jul 2026
$265.8M
Apr 2026
$257.7M
Dec 2025
$258.3M
Sep 2025
$247.8M
Jun 2025
$241.0M
Mar 2025
$233.4M
Dec 2024
$238.1M
Sep 2024
$244.4M
At each fiscal year end
Single quarter
Net margin, TTM
+6.0%
net income over revenue, 2025-06-28 to 2026-07-03
Net margin, TTM NOVT
FY Dec 2025
+5.5%
FY Dec 2024
+6.8%
FY Dec 2023
+8.3%
FY Dec 2022
+8.6%
FY Dec 2021
+7.1%
Jul 2026
+4.7%
Apr 2026
+8.2%
Dec 2025
+6.8%
Sep 2025
+4.3%
Jun 2025
+1.9%
Mar 2025
+9.1%
Dec 2024
+6.9%
Sep 2024
+7.9%
At each fiscal year end
Single quarter
Free cash flow, TTM
$114.3M
operating cash flow minus capex, 2025-06-28 to 2026-07-03
Free cash flow, TTM NOVT
FY Dec 2025
$48.4M
FY Dec 2024
$141.3M
FY Dec 2023
$100.1M
FY Dec 2022
$71.1M
FY Dec 2021
$74.6M
Jul 2026
$57.5M
Apr 2026
$47.5M
Dec 2025
$5.1M
Sep 2025
$4.2M
Jun 2025
$11.7M
Mar 2025
$27.4M
Dec 2024
$59.3M
Sep 2024
$19.5M
At each fiscal year end
Single quarter
Debt to equity
0.14x
long-term 2026-07-03 plus current 2026-07-03; equity 2026-07-03
Debt to equity NOVT
FY Dec 2025
0.19x
FY Dec 2024
0.56x
FY Dec 2023
0.53x
FY Dec 2022
0.75x
FY Dec 2021
0.83x
Jul 2026
0.14x
Apr 2026
0.18x
Dec 2025
0.19x
Sep 2025
0.56x
Jun 2025
0.57x
Mar 2025
0.51x
Dec 2024
0.56x
Sep 2024
0.62x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.58x
TTM operating cash flow over long-term 2026-07-03 plus current 2026-07-03
Cash flow to debt NOVT
FY Dec 2025
0.26x
FY Dec 2024
0.38x
FY Dec 2023
0.34x
FY Dec 2022
0.21x
FY Dec 2021
0.22x
Jul 2026
0.58x
Apr 2026
0.35x
Dec 2025
0.26x
Sep 2025
0.26x
Jun 2025
0.29x
Mar 2025
0.40x
Dec 2024
0.38x
Sep 2024
0.30x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+5.1%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on equity NOVT
FY Dec 2025
+5.2%
FY Dec 2024
+9.0%
FY Dec 2023
+11.7%
FY Dec 2022
+13.5%
FY Dec 2021
+10.1%
Jul 2026
+5.1%
Apr 2026
+5.2%
Dec 2025
+5.2%
Sep 2025
+6.8%
Jun 2025
+8.2%
Mar 2025
+9.7%
Dec 2024
+9.0%
Sep 2024
+8.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.4%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on assets NOVT
FY Dec 2025
+3.4%
FY Dec 2024
+4.9%
FY Dec 2023
+5.9%
FY Dec 2022
+6.0%
FY Dec 2021
+4.8%
Jul 2026
+3.4%
Apr 2026
+3.4%
Dec 2025
+3.4%
Sep 2025
+3.6%
Jun 2025
+4.2%
Mar 2025
+5.1%
Dec 2024
+4.9%
Sep 2024
+4.6%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+7.0%
operating income after a 22.5% effective tax rate, over long-term 2026-07-03 plus current 2026-07-03 plus average of 2025-06-27 and 2026-07-03 minus cash
Return on invested capital NOVT
FY Dec 2025
+7.0%
FY Dec 2024
+8.8%
FY Dec 2023
+11.0%
FY Dec 2022
+10.0%
FY Dec 2021
+7.1%
Jul 2026
+7.0%
Apr 2026
+6.7%
Dec 2025
+7.0%
Sep 2025
+6.5%
Jun 2025
+7.7%
Mar 2025
+9.2%
Dec 2024
+8.8%
Sep 2024
+8.0%
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.7%
operating income (EBIT proxy) over average of 2025-06-27 and 2026-07-03 minus current liabilities
Return on capital employed NOVT
FY Dec 2025
+6.7%
FY Dec 2024
+9.6%
FY Dec 2023
+10.2%
FY Dec 2022
+9.7%
FY Dec 2021
+7.1%
Jul 2026
+5.7%
Apr 2026
+6.4%
Dec 2025
+6.7%
Sep 2025
+7.4%
Jun 2025
+8.3%
Mar 2025
+9.5%
Dec 2024
+9.6%
Sep 2024
+9.1%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
91.73x
close 2026-10-26 over four quarters of diluted EPS, 2025-06-28 to 2026-07-03
P/E, trailing NOVT
FY Dec 2025
80.95x
FY Dec 2024
86.31x
FY Dec 2023
83.37x
FY Dec 2022
65.64x
FY Dec 2021
124.18x
Jul 2026
103.01x
Apr 2026
84.20x
Dec 2025
80.95x
Sep 2025
69.20x
Jun 2025
76.92x
Mar 2025
66.19x
Dec 2024
86.31x
Sep 2024
106.31x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.0B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2026-07-03 plus current 2026-07-03, minus cash 2026-07-03
Enterprise value NOVT
FY Dec 2025
$4.1B
FY Dec 2024
$5.8B
FY Dec 2023
$6.3B
FY Dec 2022
$5.2B
FY Dec 2021
$6.6B
Jul 2026
$5.3B
Apr 2026
$4.0B
Dec 2025
$4.1B
Sep 2025
$4.0B
Jun 2025
$5.0B
Mar 2025
$4.9B
Dec 2024
$5.8B
Sep 2024
$6.7B
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield NOVT
FY Dec 2025
+1.1%
FY Dec 2024
+2.6%
FY Dec 2023
+1.7%
FY Dec 2022
+1.5%
FY Dec 2021
+1.2%
Jul 2026
+2.0%
Apr 2026
+1.6%
Dec 2025
+1.1%
Sep 2025
+2.8%
Jun 2025
+2.5%
Mar 2025
+3.1%
Dec 2024
+2.6%
Sep 2024
+1.8%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -7%, PEG needs growth
PEG, trailing NOVT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
1.43x
FY Dec 2021
9.78x
Jul 2026
n/a
Apr 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
42.36x
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
NOVT ranks highest on financial health (65th percentile) and institutional and government (64th), and lowest on insider conviction (26th), among Semiconductors & Electronics peers.
Profitability
49
Inputs
Return on equity+5.1% · 56 pct, sector of 154
Return on assets+3.4% · 59 pct, sector of 171
Return on invested capital+7.0% · 24 pct, sector of 56
Return on capital employed+5.7% · 56 pct, sector of 155
Financial health
65
Inputs
Debt to equity0.14x · 58 pct, sector of 152
Cash flow to debt0.58x · 73 pct, sector of 136
Growth
38
Inputs
Revenue growth, YoY+3.3% · 38 pct, sector of 194
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
26
Inputs
Net Form 4 buying (codes P and S), 180d-$4.1M · 52 pct, sector of 146
Insider buyers, 180d0 · 0 pct, sector of 150
Institutional and government
64
Inputs
Funds adding, latest quarter243 · 68 pct, sector of 184
Congress net buyers, 365d1 · 59 pct, sector of 40
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
49
Inputs
Short interest, % of float+14.0% · 19 pct, sector of 220
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-K+6.4% · 79 pct, sector of 152
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NOVT filings, in plain words
Are Novanta insiders buying or selling NOVT?
In the 180 days to 2026-10-28, Novanta insiders were net sellers, a net $4.2M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded NOVT?
Yes. In the year to 2026-10-28, 1 House member disclosed buying NOVT and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-05-18.
Are there planned insider sales of NOVT?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $97.9K of stock; the latest, by Secor Thomas N, was filed 2026-09-11.
Read the full summary
In the 180 days to 2026-10-28, Novanta insiders were net sellers of NOVT, a net $4.2M across purchases and sales reported on Form 4 by 2 sellers. 6% of the 18 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying NOVT and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-05-18. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $97.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.